Pediatric psoriasis: an update

Silverberg, Nanette B.

doi:10.2147/tcrm.s4908

Cited by 72 publications

(80 citation statements)

References 47 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Çocukluk çağında psoriasis tedavisinde topikal ve sistemik tedaviler kullanılmaktadır (1,19). Oniki yaş altında psoriasis vulgaris tedavisi için FDA tarafından özel olarak onaylanmış herhangi bir topikal ajan yoktur (1).…”

Section: Discussionunclassified

“…Psoriasis toplumun yaklaşık %2-3,5'ini etkileyen, kronik, ataklarla seyreden, değişken klinik spektrumu olan bir hastalıktır (1)(2)(3)(4)(5). Hastaların yaklaşık %25-45'inde çocukluk veya adolesan dönemde ilk belirtiler oluşmaktadır (1)(2)(3).…”

Section: Introductionunclassified

“…Hastaların yaklaşık %25-45'inde çocukluk veya adolesan dönemde ilk belirtiler oluşmaktadır (1)(2)(3). Hastaların %10'unda hastalık 10 yaşından önce, %2'sinde ise 2 yaşından önce başlamaktadır (6).…”

Section: Introductionunclassified

“…Hastaların %10'unda hastalık 10 yaşından önce, %2'sinde ise 2 yaşından önce başlamaktadır (6). Pediatrik psoriasis başlıca infantil psoriasis, erken başlangıçlı psoriasis ve psoriatik artrite eşlik eden psoriasis olarak ayrılmaktadır (1). Şiddetli psoriasisli çocukların yaşam kalitesinin çocukluk çağı diyabet ve epilepsisinden bile daha fazla etkilendiği bilinmektedir (7).…”

Section: Introductionunclassified

See 3 more Smart Citations

The Retrospective Evaluation of Childhood Psoriasis Clinically and Demographic Features

Karadağ¹,

Bilgili²,

Çalka³

et al. 2013

tdd

View full text Add to dashboard Cite

Objective: This study was aimed to define the clinical and demographic findings of psoriasis in childhood. Methods: In this retrospective study, the data from 64 children with psoriasis admitted at the our dermatology clinic between January 2007 and January 2011 were included whose data were fully. Results: Of the patients, 37 (57.8%) were boys and 27 (42.2%) were girls. Mean age of the children was 10.08 ±3.98 years (3-16). In 10 (15%) cases, a positive family history was detected. The most frequent localizations at onset were trunk (46.9%), scalp (28.1%), knee-elbow (10.9%) and extremities (7.9%), respectively. The most commonly seen clinical types were plaque (68.8%), guttate (20.3%), palmoplantar (9.4%), pustular (1.6%), respectively. Nine children had nail involvement. Out of all patients, 21.9% had upper respiratory tract infections and 9.4% had emotional stres. Four cases were diagnosed with depression. Of the cases, two cases were on non-steroid anti-inflammatory medication, and 4 of them were on antibiotics. Systemic treatments were given to 21.9% of the cases besides topical treatments. Conclusion:The epidemiological studies of psoriasis during childhood period for different countries have been reported. In this study, the ratio shows differences when compared to those previous studies. There are few epidemiologic studies for Turkey. We believe that further epidemiological studies including large number of patients' groups will contribute the diagnosis and treatment of the disease. Key words: Psoriasis, retrospective Sonuç: Çocukluk çağında görülen Psoriasisle ilgili farklı ülkeleri kapsayan çeşitli epidemiyolojik çalışmalar mevcuttur ve bu çalışmalarda bildirilen oranlar arasında farklılıklar bulunmaktadır. Ülkemizden bildirilen az sayıda epidemiyolojik çalışma mevcuttur. Daha geniş hasta gruplarını içeren çalışmalarla sağlanacak verilerin hastalığın tanı ve tedavisine katkıda bulunacağını düşünmekteyiz.

show abstract

Section: Discussionunclassified

Section: Introductionunclassified

See 2 more Smart Citations

The Retrospective Evaluation of Childhood Psoriasis Clinically and Demographic Features

Karadağ¹,

Bilgili²,

Çalka³

et al. 2013

tdd

View full text Add to dashboard Cite

show abstract

“…De ocorrência universal e prevalência nos EUA e Europa entre 2 a 4% 3 , estima-se que afeta cerca de 1% da população brasileira 1 . Na população pediátrica a prevalência estimada varia de 0,55% a 1,4% 4 . A psoríase pustulosa palmoplantar, também conhecida como pustulose palmoplantar (PPP), é uma forma de dermatose psoriasiforme originalmente classificada no espectro da psoríase, ainda que alguns autores a considerem uma entidade distinta a partir de uma proposta do International Psoriasis Council (Conselho Internacional de Psoríase), sendo sua classificação ainda campo de intenso debate 5,6 .…”

Section: Introductionunclassified

Psoríase pustulosa palmoplantar na infância: um relato de caso

Dantas¹,

Fernandes²,

Júnior³

et al. 2017

Rev Pat Tocantins

View full text Add to dashboard Cite

Introdução: A psoríase pustulosa palmoplantar, também conhecida como pustulose palmoplantar (PPP) é uma forma de dermatose psoriasiforme caracterizada por erupções de pústulas estéreis de localização palmoplantar e simétrica. Sua prevalência é estimada entre 0,01 a 0,05%, afetando principalmente adultos do sexo feminino entre a sexta e a sétima décadas de vida. A doença é rara na faixa etária pediátrica. Desenvolvimento: No presente trabalho foi relatado um raro caso de PPP, em criança de 6 anos, destacando seu manejo hospitalar e atentando para sua dificuldade diagnóstica. Conclusão: o diagnóstico de PPP ainda é de difícil realização no Brasil. Isso pode ter relação com o perfil epidemiológico territorial, que levaria primeiramente a diagnósticos de etiologia infecciosa. Consideramos que seja pertinente um aumento do número de estudos sobre a PPP, o que ajudaria no diagnóstico precoce e redução das dificuldades físicas e psicossociais que o paciente enfrenta devido à doença. Palavras-chave: psoríase; criança; dermatopatia. Introduction: The palmoplantar pustular psoriasis, also known as palmoplantar pustulosis (PPP), is a psoriasiform dermatosis characterized by eruptions of sterile pustules with a symmetrical and palmoplantar location. It's prevalence is estimated between 0,01 to 0,05%, mainly affecting female adults in the sixth and seventh decades of life. The disease is rare in the pediatric age. Development: In the present work it was reported a rare case of PPP, in a 6 years old child, highlighting its hospital management and paying attention to the difficulty in diagnosis. Conclusion: the diagnosis of PPP is still difficult to achieve in Brazil. This may have correlation with the territorial epidemiological profile, which would lead primarily to diagnostics of infectious etiology. We consider to be relevant an increase in the number of studies about PPP, which would help with early diagnosis and reduction of the physical and psychosocial difficulties that the patient faces due to the disease. Keywords: psoriasis; child; skin diseases.

show abstract

Anti-TNF agents for paediatric psoriasis

Sanclemente

Murphy

Contreras-Ortiz

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Cochrane Database of Systematic Reviews Index (CDLQI), and adverse e ects. Our secondary outcomes included the proportion of participants achieving PASI 50 and the Physician's Global Assessment (PGA). Main results We included one study with 211 participants (median age 13 years), in which etanercept (dosage ranged from 0.8 to 50 mg per kilogram of body weight) was compared to placebo. Follow-up was over a 48-week period. At week 12, 57% versus 11% who received etanercept or placebo, respectively, achieved the PASI 75 (risk ratio 4.95, 95% confidence interval (CI) 2.83 to 8.65; high-quality evidence). Absolute risk reduction and the number needed to treat to obtain a benefit with etanercept was 45% (95% CI 33.95 to 56.40) and 2 (95% CI 1.77 to 2.95), respectively. The percentage improvement from baseline of the CDLQI scores at week 12 was better in the etanercept group than the placebo group (52.3% versus 17.5%, respectively (P = 0.0001)). Analysis between the groups showed an e ect size that was clinically important (mean di erence 2.30, 95% CI 0.85 to 3.75; high-quality evidence). However, means, medians, and minimal important di erence results and results of the Pediatric Quality of Life Inventory, Stein Impact on Family Scale, and Harter Self-Perception Profile for Children scores must be interpreted with caution, as they were not prespecified outcomes. Three serious adverse events were reported, but they were resolved without sequelae. Deaths or other events such as malignant tumours, opportunistic infections, tuberculosis, or demyelination were not reported in the included study. Also, 13% of participants in the placebo group and 53% in the etanercept group had a PGA of clear or almost clear (risk ratio 3.96, 95% CI 2.36 to 6.66; high-quality evidence) at week 12. Authors' conclusions This review found only one RCT evaluating the use of this type of biological therapy. Although the risk of publication bias was high, as we included only one industry-sponsored RCT, the risk of allocation, selection, performance, attrition, and selective reporting biases for all outcomes (except for CDLQI) was low, and no short-term serious adverse events were found. We can conclude, based on this single included study, that etanercept seems to be e icacious and safe (at least in the short term) for the treatment of paediatric psoriasis. However, as the GRADE approach refers not to individual studies but to a body of evidence, we shall wait for the results of the ongoing studies in a future update of this review. In addition, future studies should evaluate quality-of-life endpoints established a priori and standardise primary outcome measures such as PASI 75, and should include the PGA as a secondary endpoint. Also, collating and reporting adverse events uniformly is required to better evaluate safety.

show abstract

Pediatric psoriasis: an update

Cited by 72 publications

References 47 publications

The Retrospective Evaluation of Childhood Psoriasis Clinically and Demographic Features

The Retrospective Evaluation of Childhood Psoriasis Clinically and Demographic Features

Psoríase pustulosa palmoplantar na infância: um relato de caso

Anti-TNF agents for paediatric psoriasis

Contact Info

Product

Resources

About